Neuroectodermal Tumors: Clinical Trials

26 trials for Neuroectodermal Tumors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed. 26 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 426Completed 26

Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
Assessment, Questionnaire Administration, Telemedicine Visit - Astrocytoma, IDH-Mutant, Glioblastoma
Phase 4CompletedMayo Clinic302024-10-072026-04-29
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
arginine/lysine - Gastroenteropancreatic Neuroendocrine Tumors
Phase 4CompletedAdvanced Accelerator Applications422021-01-252025-01-24
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
Pembrolizumab - Carcinoma, Non-Small-Cell Lung, Melanoma
Phase 4CompletedMerck Sharp & Dohme LLC1502019-01-312025-08-29
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Octreotide, LAR Lanreotide, Questionnaires - Neuroendocrine Tumors
Phase 4CompletedMemorial Sloan Kettering Cancer Center512017-09-192025-05-09
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study
Propofol, isoflurane, sevoflurane or desflurane - Cancer, Breast, Cancer Colorectal
Phase 4CompletedPeter MacCallum Cancer Centre, Australia1692017-08-272022-06-09
Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream
5-aminolevulinic acid nanoemulsion - Lentigo Maligna
Phase 4CompletedJoint Authority for Päijät-Häme Social and Health Care102016-02-012018-05-30
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
GM-CSF, Standard of Care - Melanoma
Phase 4CompletedMayo Clinic82015-05-012020-02-10
Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
blood sampling, Nivolumab - Metastatic Melanoma
Phase 4CompletedHospices Civils de Lyon322015-04-232025-09-15
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
lanreotide acetate - NeuroEndocrine Tumours
Phase 4CompletedIpsen502014-05-012019-06-07
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
Zelboraf - Malignant Melanoma
Phase 4CompletedHoffmann-La Roche602013-10-172020-01-07
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Pasireotide, Cabergoline, Pasireotide LAR - Cushing's Disease, Acromegaly
Phase 4CompletedRECORDATI GROUP3372013-06-102024-10-01
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Everolimus, Sandostatin LAR Depot - Neoplasms
Phase 4CompletedNovartis Pharmaceuticals342013-05-142021-06-11
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
300mg vandetanib, 150mg vandetanib - Thyroid Cancer
Phase 4CompletedSanofi812012-06-082025-10-03
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
sunitinib - Well-differentiated Pancreatic Neuroendocrine Tumor
Phase 4CompletedPfizer1062012-06-062019-07-30
Phenoxybenzamine Versus Doxazosin in PCC Patients
Phenoxybenzamine, Doxazosin - Pheochromocytoma
Phase 4CompletedUniversity Medical Center Groningen1342011-12-012024-09-19
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
Everolimus (RAD001) - Neuroendocrine Tumors
Phase 4CompletedNovartis Pharmaceuticals2462011-04-272018-11-29
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
RAD001, Paclitaxel, Carboplatin - Carcinoma, Large Cell, Neuroendocrine Tumors
Phase 4CompletedNovartis Pharmaceuticals492011-04-012016-03-30
Effect of Topical Imiquimod on Lentigo Maligna
Imiquimod - Lentigo Maligna
Phase 4CompletedJerry Marsden302010-06-012012-06-20
CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
carboplatin periocular injection, CEV chemotherapy - Retinoblastoma
Phase 4CompletedSun Yat-sen University262009-01-012015-03-30
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
Aldesleukin - Metastatic Renal Cell Carcinoma, Metastatic Melanoma
Phase 4CompletedNovartis Pharmaceuticals262008-09-032021-06-08

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Melanoma (10)  ·  Neuroendocrine Tumors (8)  ·  Neoplasms (4)  ·  Brain Neoplasms (2)  ·  Carcinoid Tumor (2)  ·  Carcinoma (2)  ·  Glioblastoma (2)  ·  Hutchinson's Melanotic Freckle (2)  ·  Lung Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Pheochromocytoma (2)  ·  Prostatic Neoplasms (2)  ·  Retinoblastoma (2)  ·  Acromegaly (1)  ·  Adenoma (1)

Broader conditions

Neoplasms by Histologic Type (26)  ·  Neoplasms, Germ Cell and Embryonal (26)  ·  Neoplasms, Nerve Tissue (26)  ·  Neoplasms (22)  ·  Neoplasms by Site (16)  ·  Neuroendocrine Tumors (14)  ·  Neoplasms, Glandular and Epithelial (12)  ·  Nevi and Melanomas (12)  ·  Skin Diseases (10)  ·  Skin Neoplasms (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Carcinoma (6)  ·  Adenocarcinoma (4)  ·  Endocrine Gland Neoplasms (4)

Interventions

Everolimus (3)  ·  Carboplatin (2)  ·  Octreotide (2)  ·  Temozolomide (2)  ·  Aminolevulinic Acid (1)  ·  BF-200 ALA (1)  ·  Blood Specimen Collection (1)  ·  Cabergoline (1)  ·  Craniotomy (1)  ·  Desflurane (1)  ·  Doxazosin (1)  ·  Etanercept (1)  ·  Etoposide (1)  ·  Fibrin Tissue Adhesive (1)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  Mayo Clinic (2)  ·  Merck Sharp & Dohme LLC (2)  ·  Advanced Accelerator Applications (1)  ·  Hoffmann-La Roche (1)  ·  Hospices Civils de Lyon (1)  ·  Ipsen (1)  ·  Jagiellonian University (1)  ·  Jerry Marsden (1)  ·  Joint Authority for Päijät-Häme Social and Health Care (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  Oxford University Hospitals NHS Trust (1)  ·  Peter MacCallum Cancer Centre, Australia (1)  ·  Pfizer (1)

Countries

United States (10)  ·  Italy (5)  ·  Netherlands (5)  ·  India (4)  ·  Poland (4)  ·  United Kingdom (4)  ·  Czechia (3)  ·  France (3)  ·  Germany (3)  ·  Russia (3)  ·  South Korea (3)  ·  Spain (3)  ·  Australia (2)  ·  Belgium (2)  ·  Hungary (2)

Top investigators

A A. Franken, MD PhD (1)  ·  Bas Havekes, MD PhD (1)  ·  Boni E Elewski, MD (1)  ·  C B. Brouwer, MD PhD (1)  ·  E M. Eekhoff, MD PhD (1)  ·  Erna Snellman, Professor (1)  ·  G D. Valk, MD PhD (1)  ·  H R Haak, MD PhD (1)  ·  Henk P. Giele, MBBS FRACS (1)  ·  Huasheng Yang, M.D, PHD (1)  ·  I Eland, MD PhD (1)

Results publications

PMID 21319349, PMID 21456091, PMID 25243546, PMID 26481741, PMID 27875519, PMID 28535181, PMID 31714582, PMID 33411058, PMID 35132704, PMID 35724357, PMID 38939518, PMID 41567708

NIH funding

2019 (1)